Scan to get started on Sahi

Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ . 38K+ Ratings Google Play and App Store | IFTA Startup of the year 2025 | Forbes Asia Top 100 Startups to Watch 2026 | 8M+ downloads

Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.


Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.

Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks

Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.

Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.


High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news

Urban Company Approves QIP Issue With Floor Price Of ₹161.03 Per Share
Urban Company Limited launched its QIP issue on November 16, 2026, setting a floor price of ₹161.03 per equity share of face value ₹1. The company retains board and shareholder authorization to offer up to a 5% discount under SEBI ICDR Regulations.

Titagarh Rail Systems Targets 200 Metro Cars and 1,000 Monthly Wagons with ₹28,600 Cr Order Book
Titagarh Rail Systems targets annual production of 200 metro cars in FY27 and a monthly run-rate of 1,000 wagons by Q4 FY27. Backed by a strong order book of approximately ₹28,600 crore, the manufacturer continues to scale both its passenger and freight rolling stock capacities.

Biocon Receives US FDA Approval For Biosimilar Pebrilzo Injection
Biocon secured US FDA approval for Pebrilzo (pertuzumab-qcay), expanding its portfolio of approved US oncology biosimilars to five. Under a settlement agreement with Genentech, commercial launch in the United States is scheduled for Q3 CY2028.




